Reported 3 days ago
Viking Therapeutics, Inc. (NASDAQ:VKTX) has received a Buy rating from Oppenheimer, with a price target of $100, highlighting its promising position in the healthcare sector. Analyst Joseph Pantginis also supports this view, emphasizing the company's strong efficacy and safety data in its GLP-1 programs, which position it well for potential mergers and acquisitions despite a competitive landscape.
Source: YAHOO